09 May 2022 Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME) Member news
05 May 2022 argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia Member news
03 May 2022 reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Member news
14 Apr 2022 Mithra announces improved consolidated topline results from Donesta® Phase 3 studies and launch of recruitment for the extension of European study Member news
05 Apr 2022 Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study Member news
05 Apr 2022 Aligos Therapeutics selects drug candidate ALG-097558, a potent ritonavir-free oral protease inhibitor for the treatment and prevention of COVID-19 Member news
29 Mar 2022 Rejuvenate Biomed started a groundbreaking clinical trial and expands for future growth Member news
22 Mar 2022 argenx announces positive topline Phase 3 data from ADAPT-SC study evaluating subcutaneous efgartigimod for generalized myasthenia gravis Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
